Search Results - "Barrie, Colin"

Multidisciplinary Prehabilitation Reduces Hospitalization Time and Suggests Improved Survival in Patients with Radiologically Diagnosed Lung Cancer.

Authors: Phillips, Iain McDougall, Caleb Walton, Abi et al.

Source: Cancers. Oct2025, Vol. 17 Issue 20, p3329. 16p.

Biomarkers of systemic inflammation provide additional prognostic stratification in cancers of unknown primary.

Authors: Harvey, Svenja Stares, Mark Scott, Julie‐Anne et al.

Source: Cancer Medicine. Feb2024, Vol. 13 Issue 3, p1-10. 10p.

Immune-Related Adverse Events, Biomarkers of Systemic Inflammation, and Survival Outcomes in Patients Receiving Pembrolizumab for Non-Small-Cell Lung Cancer.

Authors: Raynes, George Stares, Mark Low, Samantha et al.

Source: Cancers. Dec2023, Vol. 15 Issue 23, p5502. 16p.

Real-World Impact of SABR on Stage I Non-Small-Cell Lung Cancer Outcomes at a Scottish Cancer Centre.

Authors: Stares, Mark Lewis, Georgina Vallet, Maheva et al.

Source: Cancers. Mar2023, Vol. 15 Issue 5, p1431. 11p.

Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer: patient experience survey.

Authors: Davies, Alexandra Phillips, Iain Barrie, Colin et al.

Source: Clinical Oncology. 2025 Supplement 1, Vol. 40, pN.PAG-N.PAG. 1p.

Early prehabilitation reduces admissions and time in hospital in patients with newly diagnosed lung cancer.

Authors: Phillips, Iain Deans, Maria Walton, Abi et al.

Source: BMJ Supportive & Palliative Care. Jan2025, Vol. 15 Issue 1, p125-129. 5p.

146 - A service improvement project to establish the supportive care needs of patients with lung cancer receiving systemic anti-cancer treatment.

Authors: Mandale, Ellie Reid, Colette Barrie, Colin et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS67-S67. 1p.

142 - Early Prehabiliation in Lung Cancer (EPIC) project: initial experience and defining the need.

Authors: Phillips, Iain Petrie, Rebecca Barrie, Colin et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS65-S65. 1p.

Characterisation and outcomes of patients referred to a regional cancer of unknown primary team: a 10-year analysis.

Authors: Stares, Mark Purshouse, Karin Knowles, Gillian et al.

Source: British Journal of Cancer. Nov2021, Vol. 125 Issue 11, p1503-1510. 8p.

159 Outcomes of thoracic radiotherapy for oligoprogression after a response to Pembrolizumab in patients with advanced Non-Small Cell Lung Cancer.

Authors: Haron, Dhania Phillips, Iain Harrow, Stephen et al.

Source: Lung Cancer (01695002). 2024 Supplement 1, Vol. 190, pN.PAG-N.PAG. 1p.

Prognostic value of the Scottish Inflammatory prognostic Score in patients with NSCLC expressing PD-L1 ≥ 50 % progressing on first-line pembrolizumab.

Authors: Stares, Mark Doyle, Emma Chapple, Sally et al.

Source: Lung Cancer (01695002). Mar2024, Vol. 189, pN.PAG-N.PAG. 1p.

114 - Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy.

Authors: Langley, Benjamin Leach, James Fenner, Florence et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS53-S54. 2p.

69 - The Scottish Inflammatory Prognostic Score (SIPS) identifies poor responders to first-line chemoimmunotherapy in non-small cell lung cancer.

Authors: Raynes, George Price, Gareth Yan, Xiangfei et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS33-S34. 2p.

A predictive tool for assessing bone lesions in malignancy of undefined primary origin.

Authors: Stares, Mark Yong, Guo Liang O'Reilly, Sean et al.

Source: Clinical Oncology. 2022 Supplement 2, Vol. 34, pe2-e2. 1p.

124 - Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?

Authors: Leach, James Stares, Mark Langley, Benjamin et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS58-S58. 1p.

70 - Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre.

Authors: Yan, Xiangfei Price, Gareth Raynes, George et al.

Source: Lung Cancer (01695002). 2022 Supplement 1, Vol. 165, pS34-S34. 1p.

157 - Audit of cyclophosphamide/adriamycin/vincristine (CAV) chemotherapy use in Edinburgh Cancer Centre.

Authors: Boh, Zhuang Little, Felicity MacKean, Melanie et al.

Source: Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS65-S65. 1p.

103 - Scottish Immunotherapy Prognostic Score: biomarker of systemic inflammation predicts response to first-line pembrolizumab for metastatic non-small cell lung cancer.

Authors: Ding, Tze-en Grace Thomson, Findlay Stratton, Cory et al.

Source: Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS43-S43. 1p.

80 - Real world prospective data on tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor mutation positive non-small cell lung cancer at the Edinburgh Cancer Centre.

Authors: Swan, Amanda Boh, Zhuang Patrizio, Ailsa et al.

Source: Lung Cancer (01695002). Jun2021:Supplement 1, Vol. 156, pS32-S32. 1p.

Challenging presentations of germ cell tumours in routine clinical practice.

Authors: Bezawada N Norton A Mactier K et al.

Source: The journal of the Royal College of Physicians of Edinburgh [J R Coll Physicians Edinb] 2021 Mar; Vol. 51 (1), pp. 53-57.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 101144324 Publication Model: Print Cited Medium: Internet ISSN: 2042-8189 (Electronic) Linking ISSN: 14782715 NLM ISO Abbreviation: J R Coll Physicians Edinb Subsets: MEDLINE